Propanc Biopharma, Inc. — fact timeline

Propanc Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 31, 2025, Propanc Biopharma, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “ Bid Price Requirement ”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bi”

Propanc Biopharma, Inc.: Filed Certificate of Designation creating Series C Preferred Stock as an amendment to the Certificate of Incorporation (effective 2025-11-04).

“On November 4, 2025, the Company amended its Certificate of Incorporation and filed a Certificate of Designation with the Delaware Secretary of State that authorized the issuance of up to 9,900 shares of a new series of preferred stock, par value $0.01 per share, designated as “Series C Preferred Stock” for which the Board established the rights, preferences and limitations thereof.”

Propanc Biopharma, Inc. incurred convertible notes of $112,350 at 22% per annum maturing April 30, 2026.

“Effective July 25, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $112,350 (the “Note”)”

Propanc Biopharma, Inc. incurred convertible notes of $82,500 with an accredited investor at 10% per annum maturing September 15, 2025.

“Effective July 18, 2025, Propanc Biopharma, Inc. (the “Company”) issued a Promissory Note to an accredited investor (the “Investor”) in the aggregate principal amount of 82,500 (the “Note”), for a purchase price of $75,000.”

Propanc Biopharma, Inc. incurred convertible notes of $67,860.00 with an investor at one-time interest charge of fifteen percent (15%) maturing April 16, 2026.

“with an investor (the “Investor”) pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $67,860.00 (the “Note”), for a purchase price of $58,000. The Company intends to use the net proceeds therefrom for general working capital purposes. The maturity date of the Note is April”

Propanc Biopharma, Inc. incurred loan of $13,188 AUD with one of our members of the Board of Directors (the “Board Member”) at 12% per annum maturing June 30, 2025.

“Effective Junel 13, 2025, the Company entered into and closed a loan agreement (the “Loan”) with one of our members of the Board of Directors (the “Board Member”), pursuant to which the Board Member loaned the Company an aggregate principal amount of $13,188 AUD.”

Propanc Biopharma, Inc. incurred convertible notes of $25,000 with an investor at 8% per annum maturing June 12, 2026.

“Effective June 12, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $25,000 (the “Note”), for a purchase price of $22,500.”

Propanc Biopharma, Inc. incurred loan of $60,000 with an accredited investor at ten percent (10%) per annum maturing July 15, 2025.

“Effective June 2, 2025, Propanc Biopharma, Inc. (the “Company”) issued a Promissory Note to an accredited investor (the “Investor”) in the aggregate principal amount of $60,000 (the “Note”), for a purchase price of $50,000.”

Propanc Biopharma, Inc. entered into Maturity Extension Agreement with Ionic Ventures, LLC (effective 2024-05-10).

“On May 10, 2024, Propanc Biopharma, Inc. (the “Company”) entered into a Maturity Extension Agreement (the “Extension Agreement”) with Ionic Ventures, LLC (the “Ionic”), pursuant to which the Ionic agreed to extend the maturity date of original 10% OID Promissory Note issued on August 15, 2023 (the “Original Note”) to September 30, 2024.”

Propanc Biopharma, Inc. incurred convertible notes of $27,500 with an investor at eight percent (8%) per annum maturing October 12, 2024.

“Effective April 16, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $27,500 (the “Note”), for a purchase price of $25,000.”

Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the “Investor”) valued at aggregate principal amount of $27,500 (effective 2024-04-16).

“Effective April 16, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $27,500 (the “Note”), for a purchase price of $25,000.”

Propanc Biopharma, Inc. incurred convertible notes of $50,000 with an investor at eight percent (8%) per annum, which may be increased to sixteen percent (16%) in maturing March 1, 2024.

“Effective March 5, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $50,000 (the “Note”), for a purchase price of $46,875.”

Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at $50,000 (effective 2024-03-05).

“Effective March 5, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $50,000”